AGA
ALNY icon

Altrinsic Global Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Altrinsic Global Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,700
Closed -$1.01M – 86
2017
Q2 		$1.01M Sell
12,700
-50,000
-80% -$3.2M 0.04% 77
2017
Q1 		$3.21M Sell
62,700
-40,000
-39% -$1.85M 0.11% 63
2016
Q4 		$3.85M Buy
102,700
+30,000
+41% +$1.26M 0.14% 60
2016
Q3 		$4.93M Hold
72,700
– – 0.18% 57
2016
Q2 		$4.03M Buy
72,700
+5,000
+7% +$315K 0.11% 62
2016
Q1 		$4.25M Buy
+67,700
New +$4.5M 0.12% 65

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Altrinsic Global Advisors's ALNY Position: Q3 2017 in Review

Altrinsic Global Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2017, closing a stake of 12,700 shares — an estimated $1.01M sold.

Altrinsic Global Advisors first reported a position in ALNY in Q1 2016 and held it in 6 quarters. The position peaked at $4.93M in Q3 2016. 236 funds tracked by Wall St. Rank hold ALNY as of Q3 2017.

  • Altrinsic Global Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Altrinsic Global Advisors sold 12,700 Alnylam Pharmaceuticals shares in Q3 2017, an estimated $1.01M.
  • Altrinsic Global Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Altrinsic Global Advisors's Alnylam Pharmaceuticals position peaked at $4.93M in Q3 2016.
  • 236 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2017.

Based on Altrinsic Global Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.